Contains Vitamin B12 as an injectable form of CYANOCOBALAMIN, for use in anaemias resulting from B12 deficiency in horses, cattle, dogs and cats
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Their personalized approach focuses on supporting overall wellness, vitality, and nutritional balance through individualized care
Diabetes Ther 12, 13251339 (2021)
NNMT inhibition increases NAD+ availability, which is known to support mitochondrial function, reduce fibrosis, and lower inflammation
What's included in this stack Metabolic Cut - Start - Focused Three-Compound Metabolic Research Stack Rttrutd GLP-1/GIP/GCG agonism Rttrutd, 5-Amino-1MQ lipid oxidation Rttrutd, 5-Amino-1MQ respiration enhances insulin secretion, sensitivity Slu-pp-332, 5-Amino-1MQ stimulation maintains muscle during fat loss reduces cytokines, boosts antioxidants Slu-pp-332 oxidative fiber upregulation Description Mechanism of Action This research bundle is designed to investigate a multi-pathway approach to metabolic regulation